Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | CD40 | P25942 | 1/20 | 0.40 |
| ▸ | CD40LG | P29965 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9508860 | 0.90 | P2RY12 (0.44) | TERTP2RY12ITGB3ITGA2BMEN1 | |
| SCHEMBL6519579 | 0.89 | TERT (0.48) | TERTCD40CD40LGMEN1KMT2A | |
| SCHEMBL2704274 | 0.86 | ALDH1A1 (0.50) | TERTMEN1KMT2A | |
| SCHEMBL2705691 | 0.86 | POLB (0.50) | MEN1KMT2A | |
| SCHEMBL4447236 | 0.83 | EGFR (0.46) | MEN1KMT2A | |
| SCHEMBL11067406 | 0.83 | SMN1; SMN2 (0.53) | — | |
| SCHEMBL11489249 | 0.82 | LMNA (0.52) | — | |
| SCHEMBL14093907 | 0.81 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL1156215 | 0.81 | PEPD (0.42) | CD40CD40LGMEN1KMT2A | |
| SCHEMBL9475174 | 0.79 | CNR1 (0.43) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414327-B1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2010112116-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | TERT 560/4885HTR6 1785/4885HTR2C 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.